Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5144/0256-4947.2002.108 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Blastic Plasmacytoid Dendritic Cell Neoplasm, a Very Rare Hematological Malignancy With Initial Cutaneous Involvement: A Case Report.
Acta Dermatovenerol Croat
November 2024
Prof. Miloš Nikolić, MD, PhD, University of Belgrade, School of Medicine,, Belgrade, Serbia;
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare and aggressive hematologic malignancy, arising from plasmacytoid dendritic cells (pDCs). BPDCN frequently has, at least initially, exclusively cutaneous presentation. We present a 45-year-old woman with a 3-month history of rapidly evolving violaceous patches, infiltrated plaques, and bruise-like tumefactions, disseminated on her face and upper trunk.
View Article and Find Full Text PDFEfficacy of thiotepa-conditioned autologous stem-cell transplantation as consolidation therapy for primary leptomeningeal malignant lymphoma: a case report and review of literature.
Ann Hematol
December 2024
Department of Hematology, Yokosuka Kyosai Hospital, 1-16 Yonegahamadori, Yokosuka, Kanagawa, Japan.
Article Synopsis
- Primary leptomeningeal malignant lymphoma (PLML) is a rare form of primary central nervous system lymphoma (PCNSL) with no established treatment due to its uniqueness.* -
- A case study of a 46-year-old male with PLML showed complete remission after treatment with a combination of chemotherapy (R-MPV and intrathecal agents) and autologous stem-cell transplantation (ASCT) using a thiotepa regimen.* -
- A literature review indicated that ASCT has been successfully used in three reported cases of PLML, suggesting it may be an effective consolidation therapy, but more research is necessary to develop standardized treatment guidelines.*
Methotrexate-induced leukoencephalopathy presenting as acute-onset limb weakness in a child: a case report.
J Med Case Rep
September 2024
Colombo North Teaching Hospital, Ragama, Sri Lanka.
Article Synopsis
- Methotrexate is a key medication for treating childhood cancers like acute lymphoblastic leukemia but can lead to severe side effects such as neurotoxicity, specifically leukoencephalopathy, which usually presents with gradual neurological symptoms.
- A case involving a 10-year-old boy showed acute neurological symptoms, including limb weakness and involuntary movements, after taking oral methotrexate, a rare occurrence compared to traditional administration routes like injection.
- MRI scans revealed brain abnormalities consistent with methotrexate-induced neurotoxicity, highlighting the need for careful monitoring of neurological effects even with oral use of the drug.
[A multicenter study on effect of delayed chemotherapy on prognosis of Burkitt lymphoma in children].
Zhonghua Er Ke Za Zhi
October 2024
Department of Hematology & Oncology, Children's Hospital Affiliated to Shandong University(Jinan Children's Hospital), Jinan 250022, China.
Article Synopsis
- The study aimed to identify factors that affect delays in chemotherapy for children with Burkitt lymphoma and how these delays impact patient outcomes.
- It analyzed clinical data from 591 children in China, looking at various characteristics and the reasons behind chemotherapy delays, such as severe infections and bone marrow suppression.
- The findings showed that 12.4% of patients experienced chemotherapy delays, and the overall survival rate was high at 92.5%, suggesting that while delays are problematic, most patients still fared well.
Case Report: A successful outcome of nadroparin calcium therapy for cerebral venous sinus thrombosis in a child with acute lymphoblastic leukemia.
Front Pediatr
September 2024
Department of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen, China.
Background: The appearance of cerebral venous sinus thrombosis (CVST) in childhood acute lymphocytic leukemia (ALL) is a rare life-threatening disease that can cause significant morbidity, neurological sequelae, and potentially poor outcomes.
Case Presentation: We present the case of a 13-year-old boy with ALL who developed CVST and intrinsic hemorrhage approximately 30 days after receiving chemotherapy with vincristine, dexamethasone, daunorubicin, and pegylated-asparaginase (PEG-Asp). He complained of a severe headache and then developed a generalized seizure at night.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!